Reduced expression of CYLD in human colon and hepatocellular carcinomas

Carcinogenesis

Volumn 28, Issue 1, 2007, Pages 21-27

  Hellerbrand, Claus ^a   Bumes, Elisabeth ^a   Bataille, Frauke ^a   Dietmaier, Wolfgang ^a   Massoumi, Ramin ^b   Bosserhoff, Anja K ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN CYLD; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CLINICAL ARTICLE; COLON CARCINOGENESIS; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOWN-REGULATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HEPATOCYTES; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 33845679104     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl081     Document Type: Article

References (32)

1. Mayo,M.W. and Baldwin,A.S. (2000) The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim. Biophys. Acta, 1470, M55-M62.
2. Pahl,H.L. (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene, 18, 6853-6866.
3. Baldwin,A.S. (2001) Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest., 107, 241-246.
4. Karin,M., Cao,Y., Greten,F.R. and Li,Z.W. (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer, 2, 301-310.
5. Gilmore,T.D. (1999) Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene, 18, 6925-6937.
6. Hacker,H. and Karin,M. (2002) Is NF-kappaB2/p100 a direct activator of programmed cell death? Cancer Cell, 2, 431-433.
7. Block,T.M., Mehta,A.S., Fimmel,C.J. and Jordan,R. (2003) Molecular viral oncology of hepatocellular carcinoma. Oncogene, 22, 5093-5107.
8. Arsura,M. and Cavin,L.G. (2005) Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett., 229, 157-169.
9. Pikarsky,E., Porat,R.M., Stein,I., Abramovitch,R., Amit,S., Kasem,S., Gutkovich-Pyest,E., Urieli-Shoval,S., Galun,E. and Ben Neriah,Y. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 431, 461-466.
10. Lind,D.S., Hochwald,S.N., Malaty,J., Rekkas,S., Hebig,P., Mishra,G., Moldawer,L.L., Copeland,E.M.III and Mackay,S. (2001) Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery, 130, 363-369.
11. Yu,H.G., Yu,L.L., Yang,Y., Luo,H.S., Yu,J.P., Meier,J.J., Schrader,H., Bastian,A., Schmidt,W.E. and Schmitz,F. (2003) Increased expression of Re1A/nuclear factor-kappa B protein correlates with colorectal tumorigenesis. Oncology, 65, 37-45.
12. Ghosh,S., May,M.J. and Kopp,E.B. (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol., 16, 225-260.
13. Ghosh,S. and Karin,M. (2002) Missing pieces in the NF-kappaB puzzle. Cell, 109 (Suppl), S81-S96.
14. Senftleben,U., Cao,Y., Xiao,G. et al. (2001) Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science, 293, 1495-1499.
15. Dejardin,E., Droin,N.M., Delhase,M., Haas,E., Cao,Y., Makris,C., Li,Z.W., Karin,M., Ware,C.F. and Grren,D.R. (2002) The lymphotoxinbeta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity, 17, 525-535.
16. Bignell,G.R., Warren,W., Seal,S. et al. (2000) Identification of the familial cylindromatosis tumour-suppressor gene. Nat. Genet., 25, 160-165.
17. Brummelkamp,T.R., Nijman,S.M., Dirac,A.M. and Bemards,R. (2003) Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature, 424, 797-801.
18. Reiley,W., Zhang,M. and Sun,S.C. (2004) Negative regulation of JNK signaling by the tumor suppressor CYLD. J. Biol. Chem., 279, 55161-55167.
19. Trompouki,E., Hatzivassiliou,E., Tsichritzis,T., Farmer,H., Ashworth,A. and Mosialos,G. (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature, 424, 793-796.
20. Weiss,T.S., Jahn,B., Cetto,M., Jauch,K.W. and Thasler,W.E. (2002) Collagen sandwich culture affects intracellular polyamine levels of human hepatocytes. Cell Prolif., 35, 257-267.
21. Muhlbauer,M., Allard,B., Bosserhoff,A.K., Kiessling,S., Herfarth,H., Rogler,G., Scholmerich,J., Jobin,C. and Hellerbrand,C. (2004) Differential effects of deoxycholic acid and taurodeoxycholic acid on NF-kappa B signal transduction and IL-8 gene expression in colonic epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol., 286, G1000-G1008.
22. Behrmann,I., Wallner,S., Komyod,W., Heinrich,P.C., Schuierer,M., Buettner,R. and Bosserhoff,A.K. (2003) Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am. J. Pathol., 163, 683-690.
23. Massoumi,R., Chmielarska,K., Hennecke,K., Pfeifer,A. and Fässler,R. (2006) CYLD inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kB signalling. Cell, 125, 665-677.
24. Pinte,S., Stankovic-Valentin,N., Deltour,S., Rood,B.R., Guerardel,C. and Leprince,D. (2004) The tumor suppressor gene HIC1 (hypermethylated in cancer 1) is a sequence-specific transcriptional repressor: Definition of its consensus binding sequence and analysis of its DNA binding and repressive properties. J. Biol. Chem., 279, 38313-38324.
25. Ahuja,N., Li,Q., Mohan,A.L., Baylin,S.B. and Issa,J.P. (1998) Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res., 58, 5489-5494.
26. Kanai,Y., Hui,A.M., Sun,L., Ushijima,S., Sakamoto,M., Tsuda,H. and Mrohashi,S. (1999) DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis. Hepatology, 29, 703-709.
27. Schmitz,G. and Langmann,T. (2005) Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. Biochim. Biophys. Acta, 1735, 1-19.
28. Jono,H., Lim,J.H., Chen,L.F., Xu,H., Trompouki,E., Pan,Z.K., Mosialos,G. and Li,J.D. (2004) NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: Evidence for a novel inducible autoregulatory feedback pathway. J. Biol. Chem, 279, 36171-36174.
29. Costello,C.M., Mah,N., Hasler,R. et al. (2005) Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med., 2, e199.
30. Eaden,J.A., Abrams,K.R. and Mayberry,J.F. (2001) The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut, 48, 526-535.
31. Rutter,M., Saunders,B., Wilkinson,K., Rumbles,S., Schofield,G., Kamm,M., Williams,C., Price,A., Talbot,I. and Forbes,A. (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology, 2004, 126, 451-459.
32. Lin,A. and Karin,M. (2003) NF-kappaB in cancer: A marked target. Semin. Cancer Biol., 13: 107-114.